Approximately 30% of IBD patients do not respond to anti-TNF therapy (PNR: primary non-response), and nearly half of patients who respond to anti-TNF therapy lose clinical benefit within the first year, requiring dose escalation or treatment modification (LOS: secondary loss of response) [8,9]. This evidence concerns the gene TNF and inflammatory bowel disease.